Serum Hepatocyte-Derived Fibrinogen-Related Protein-1: A Novel Biomarker for Severity and Clinical Outcome in Acute Ischemic Stroke Authors: Fang Liang, Xia Li, Liangnian Wei, Rong Chen, Kaijing Zhang, Ling Wu, Yiting Hua, Wenlei Li, Yuan Zhu, Shijia Liu, Chunbing Zhang, Pengfei Li Published: 2026 ABSTRACT ObjectiveThis work was designed to investigate the expression of hepatocyte-derived fibrinogen-related protein-1 (HFREP1) and its clinical value in patients with first-ever acute ischemic stroke (AIS).MethodsA total of 222 newly diagnosed patients with first-onset AIS admitted to the Encephalopathy Center of Jiangsu Province Hospital of Chinese Medicine from April 2023 and September 2024 were enrolled as the AIS group. Besides, 89 healthy individuals matched for age and sex were included in the control cohort. Baseline demographic characteristics and laboratory indicators were gathered from all enrolled subjects. Serum HFREP1 levels were determined using the enzyme-linked immunosorbent assay (ELISA) method. Spearman correlation analysis was adopted to analyze the correlation between HFREP1 expression and other laboratory indexes. Logistic regression was applied to identify independent factors affecting the severity and short-term prognosis of AIS. Receiver operating characteristic (ROC) curve analysis was further performed to assess the predictive efficacy of serum HFREP1 for AIS severity and short-term clinical outcome.ResultsCompared with the control group, the AIS group presented obviously higher serum HFREP1 concentrations (P<0.001). Moreover, HFREP1 levels were notably increased in patients with moderate-to-severe stroke (P<0.001) and those with poor short-term prognosis (P<0.05). Elevated serum HFREP1 levels were positively correlated with National Institutes of Health Stroke Scale (NIHSS) scores (rs=0.22, P=0.001), neutrophil count (rs=0.17, P<0.01), and neutrophil-to-lymphocyte ratio (NLR) (rs=0.22, P<0.01). Univariate analysis indicated that elevated HFREP1 levels were significantly associated with severe stroke and adverse short-term prognosis. After multivariate confounding adjustment, HFREP1 levels remained independently correlated with severe stroke in Model 4 [odds ratio (OR)=1.004, 95% confidence interval (CI):1.000–1.008, P=0.039] and unfavorable short-term prognosis in Model 2 (OR=1.004, 95% CI:1.000–1.007, P=0.041). ROC curve analysis revealed that HFREP1 exhibited a favorable predictive performance for stroke severity [area under the curve (AUC)=0.665, 95% CI:0.573–0.756, P<0.01] and short-term prognosis (AUC=0.617, 95% CI:0.503–0.732, P<0.05). Overall, the optimal cut-off value of HFREP1 was 35.35 ng/mL for identifying AIS, and 68.45 ng/mL for evaluating stroke severity and predicting adverse prognosis.ConclusionElevated serum HFREP1 level might act as a novel and promising early biomarker for evaluating disease severity and predicting poor short-term prognosis in patients with first-onset AIS. Introduction Stroke is a common, frequently occurring, and intractable disease that predominantly affects middle-aged and older adults. Globally, it ranks as the second most common cause of mortality and the third leading contributor to disability.1 Studies have shown that timely administration of thrombolysis combined with vascular interventional therapy within 4.5 hours of onset can effectively lower the mortality and disability rates in acute ischemic stroke (AIS) and improve patient prognosis.2 Despite its significant therapeutic benefits, this approach has certain limitations, including the risk of ischemia/reperfusion injury. Currently, the diagnosis of AIS mainly relies on imaging examinations, however, these methods fail to detect asymptomatic cerebral infarctions at an early stage and are relatively expensive. Furthermore, there is a lack of effective biomarkers for prognostic assessment in AIS. Therefore, identifying novel and reliable biomarkers for the diagnosis and prognostic evaluation of AIS is of great significance for improving patient outcomes. In fact, although successful reperfusion can enhance the supply of oxygen and leukocytes to the ischemic area, it may also lead to an increase in inflammatory mediators, thereby exacerbating neuronal death.3 Since inflammation plays a core part in the pathophysiological process of ischemic stroke (IS), it has long been regarded as both a prognostic biomarker and a potential therapeutic target. However, to date, no anti-inflammatory neuroprotective strategy has been successfully translated from the laboratory to clinical practice. Routine circulating inflammation biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), and lipoprotein-associated phospholipase A2 (LP-PLA2), lack sufficient sensitivity, specificity, rapidity, and precision, failing to fully reflect the complex pathophysiological cascade of acute stroke.4 Thus, the discovery of novel, non-invasive and reliable biomarkers is urgently needed to improve early assessment and prognostic prediction for AIS patients. Hepatocyte‑derived fibrinogen‑related protein 1 (HFREP1), alternatively named fibrinogen‑like protein 1 (FGL1) or hepassocin, was first discovered in hepatocytes and participates in metabolic regulation as well as liver regeneration. Recently, it has garnered widespread attention owing to its overexpression in a variety of human tumors.5,6 Accumulating evidence has demonstrated that serum HFREP1 has potential biomarker value for diabetes,7 psoriasis severity,8 and polycystic ovary syndrome.9 Notably, HFREP1 is an acute‑phase reactive protein and can be regulated by inflammatory cytokines including IL-6.10 Our research group has verified that HFREP1 not only possesses diagnostic efficacy against rheumatoid arthritis (RA) but also enables the assessment of disease activity and the prediction of RA progression.11,12 We have also found that in community-acquired pneumonia with sepsis, HFREP1 was strongly correlated with CRP and procalcitonin, and its diagnostic performance was comparable to that of procalcitonin.13 Despite the well-documented biological functions of HFREP1 in inflammatory and metabolic disorders, no previous clinical or basic research has investigated the expression pattern, clinical correlation or prognostic significance of serum HFREP1 in AIS patients. Growing evidence indicates that HFREP1 acts not only as a non-specific inflammatory mediator but also might participate in cerebral ischemic injury through inflammatory signaling pathways. Its transcriptional expression can be directly modulated via the IL-6/STAT3 signaling cascade,14 a core pathway activated rapidly following cerebral ischemia and reperfusion. AIS triggers robust local neuroinflammation and systemic inflammatory responses, driving IL-6 release and subsequent STAT3 activation,15 and may further drive the alteration of circulating HFREP1 levels. This molecular cascade provides a plausible mechanistic basis to explain circulating HFREP1 fluctuations after stroke, rather than changes secondary to generalized inflammation alone. Accordingly, the current research was designed to clarify the clinical implication of circulating HFREP1 in AIS, offering novel support for the diagnosis, management and prognostic evaluation of AIS. Materials and Methods Ethic Approval All procedures in this study were performed in accordance with the Declaration of Helsinki, and the research protocol was approved by the Ethics Committee in Affiliated Hospital of Nanjing University of Traditional Chinese Medicine (20230930). Sample Size and Power Calculation Sample size estimation was performed using G*Power software (version 3.1). The calculation was based on a two-sided independent samples t-test with a significance level of α=0.05 and a statistical power of 80% (1−β=0.80).16 Based on preliminary experimental data, the effect size was estimated as Cohen’s d=0.57. Considering the expected ratio between the poor prognosis and favorable prognosis groups (approximately 1:5.67), the minimum required sample size was calculated to be 188 participants. Assuming a potential dropout rate of 15%, the final sample size was increased to approximately 222 participants. Study Participants From April 2023 to September 2024, a total of 384 patients with AIS were enrolled at the Encephalopathy Center of Jiangsu Province Hospital of Chinese Medicine. The eligibility requirements for participants are listed below: (1) diagnosis of AIS confirmed by cranial MRI or CT and based on the American Stroke Association Guideline.17 (2) age ≥18 years; (3) hospitalization within 48 hours after symptom onset; (4) first-ever onset of AIS. The exclusion criteria were defined as follows: (1) prior history of stroke; (2) transient ischemic attack (TIA); (3) other neurological diseases; (4) inflammatory or immune system disorders; (5) acute infections in any system (respiratory, digestive, urinary, reproductive, or bloodstream); (6) concomitant tumors or hematologic malignancies; (7) severe cardiac, hepatic, or renal dysfunction; (8) pregnancy or lactation. According to the inclusion and exclusion criteria, 222 AIS patients were eventually included in the study. In parallel, 89 age- and gender-matched individuals free of cerebrovascular disorders were recruited from the hospital’s physical examination center during the same period to serve as the controls. These control participants had no stroke-like symptoms and met the identical exclusion criteria adopted for the AIS cohort. All enrolled participants signed written informed consent before taking part in this study. Stroke Subtype, Severity and Outcome Assessment AIS subtypes were classified based on the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria.18 Accordingly, all enrolled AIS cases were further divided into five etiological categories: large-artery atherosclerosis, cardioembolic stroke, small‑vessel disease, stroke with other identified causes, and stroke of undetermined origin. Stroke severity and functional outcome were assessed via the National Institutes of Health Stroke Scale (NIHSS)19 and the modified Rankin Scale (mRS), respectively. Relevant scores were documented at hospital admission and at the 3‑month follow‑up after discharge. Patients were stratified into mild stroke (NIHSS<6) and moderate‑to‑severe stroke (NIHSS≥6) subgroups according to admission NIHSS values. For prognostic assessment at 90 days post‑onset, mRS scores of 0–2 were defined as favorable functional outcome, while scores ranging from 3 to 6 were regarded as poor prognosis. Clinical Data Collection and Laboratory Test All clinical information analyzed in this research was extracted from inpatient medical records of our hospital. Baseline characteristics: age, sex, body mass index (BMI), medical histories (hypertension, atrial fibrillation, hyperlipidemia, diabetes), smoking, drinking, treatment after admission (antiplatelet, anticoagulation, antihypertensive drugs, hypoglycemic agents, lipid-lowering agents, thrombolysis therapy) were obtained. In addition, we gathered systolic blood pressure (SBP), diastolic blood pressure (DBP), as well as NIHSS and mRS scores at admission. Blood samples were collected from all participants under fasting conditions: AIS patients underwent venous blood sampling within 24 hours of hospitalization, while healthy controls were sampled on the day of their physical examination. For each subject, 2 mL of venous blood was drawn into EDTA-K2 anticoagulant tubes, and another 2 mL was collected into plain serum tubes. Blood specimens in plain tubes were left to stand at room temperature for 30 min, followed by centrifugation at 3000 g for 15 min to isolate serum. The harvested serum aliquots were preserved in a −80°C freezer pending subsequent detection. Serum biochemical indicators including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and fasting blood glucose (FBG) were assayed using an automatic biochemical analyzer (AU5800, Beckman Coulter, Brea, CA, USA). Routine blood parameters such as white blood cell (WBC), red blood cell (RBC), neutrophil (NEU), lymphocyte (LYM) and platelet (PLT) counts were detected with an automated hematology analyzer (XN‑1000, Sysmex, Kobe, Japan). The neutrophil-to-lymphocyte ratio (NLR) values were obtained via the calculation of the ratio of absolute neutrophil count to absolute lymphocyte count. Enzyme-Linked Immunosorbent Assay The concentration of serum HFREP1 was determined by a human HFREP1 ELISA kit (Jiangsu Pinsheng Medical Technology Co., Ltd., Nanjing, Jiangsu, China) according to the manufacturer’s instructions. Statistical Analysis All statistical analyses were carried out with SPSS 26.0 software, and all graphs were plotted using GraphPad Prism 6.01. According to the normality of data distribution, continuous variables were presented as mean ± standard deviation (SD) or median with interquartile range (IQR). Categorical variables were described as case numbers and constituent ratios (percentages). The Kolmogorov–Smirnov test was used for normality testing, and Levene’s test was adopted to assess the homogeneity of variance. For intergroup comparison of continuous data, the independent sample t-test or Mann–Whitney U-test was selected correspondingly. The chi-square (χ2) test was used for comparison of categorical variables. Spearman correlation analysis was adopted to explore the correlation relationships between related indicators. Logistic regression analysis was performed to screen risk factors for AIS, and the results were reported as odds ratio (OR) together with 95% confidence interval (CI). Receiver operating characteristic (ROC) curves were established to assess the diagnostic efficacy of HFREP1 in AIS. A two-tail P value less than 0.05 was defined as statistically significant. Results Demographics and Baseline Characteristics of Enrolled Study Subjects For the study, a total of 384 patients who were suspected of having an AIS were initially screened. The flow-chart of the current study was shown as Figure 1. Eventually, a total of 222 patients with AIS were enrolled in this study, with 89 healthy participants recruited as the control group. The baseline characteristics of both the AIS cohort and the control cohort are compiled in Table 1. In comparison to the control group, the AIS group showed notably higher proportions of hypertension, diabetes, and atrial fibrillation history, along with elevated levels of WBC, NEU, FPG, and NLR. In contrast, the levels of HDL-C and TC were significantly lower in the AIS group. All these observed differences reached statistical significance (P<0.05), with detailed data presented in Table 1.Table 1Comparison of Demographic and Clinical Characteristics Between AIS and Controls GroupsCharacteristicsControls (n=89)AIS (n=222)PAge, years62(60,67)66(59.75,72)0.099Male, n (%)58(65.17)152(68.47)0.573BMI, kg/m224.5(22.1,26.5)24.0(22.43,26.0)0.951Smoking history, n (%)22(24.7)75(33.8)0.137Medical history, n (%)Hypertension, n (%)51(57.30)163(73.42)0.006Hyperlipidemia, n (%)8(8.99)26(11.71)0.487Diabetes mellitus, n (%)5(5.62)87(39.19)<0.001Atrial fibrillation, n (%)0(0)23(9.91)0.002Ischemic heart disease, n (%)1(1.12)13(5.86)0.076WBC, × 109/L5.67(4.95,6.49)7.22(5.90,8.81)<0.001RBC, ×1012/L4.81(4.42,5.02)4.70(4.33,4.97)0.171LYM, ×109/L1.85 (1.63,2.13)1.80(1.35,2.24)0.182NEU, ×109/L3.20(2.69,3.78)4.45(3.38,6.17)<0.001PLT, ×109/L215(180.3,246.3)200(170.8,233.5)0.068NLR1.68(1.38,2.03)2.55(1.67,3.66)<0.001TC, mmol/L4.88(4.29,5.47)4.48(3.7,5.5)0.006TG, mmol/L1.27(1.01,1.65)1.31(1.03,1.94)0.299LDL-C, mmol/L2.90(2.28,3.55)2.63(2.13,3.39)0.062HDL-C, mmol/L1.26(1.11,1.45)1.14(0.97,1.31)<0.001FBG, mmol/L5.25(4.79,5.69)6.30(5.24,8.38)<0.001Abbreviations: BMI, Body Mass Index; WBC, white blood cell count; LYM, lymphocyte count; NEU, neutrophil count; NLR, neutrophil-to-lymphocyte ratio; RBC, red blood cell count; PLT, platelet count; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FBG, fasting blood glucose. Figure 1Flow-chart describing the selection of AIS patients for the study.Flowchart of AIS patient selection for a study, showing screening, exclusion and enrollment steps. Table 1Comparison of Demographic and Clinical Characteristics Between AIS and Controls GroupsCharacteristicsControls (n=89)AIS (n=222)PAge, years62(60,67)66(59.75,72)0.099Male, n (%)58(65.17)152(68.47)0.573BMI, kg/m224.5(22.1,26.5)24.0(22.43,26.0)0.951Smoking history, n (%)22(24.7)75(33.8)0.137Medical history, n (%)Hypertension, n (%)51(57.30)163(73.42)0.006Hyperlipidemia, n (%)8(8.99)26(11.71)0.487Diabetes mellitus, n (%)5(5.62)87(39.19)<0.001Atrial fibrillation, n (%)0(0)23(9.91)0.002Ischemic heart disease, n (%)1(1.12)13(5.86)0.076WBC, × 109/L5.67(4.95,6.49)7.22(5.90,8.81)<0.001RBC, ×1012/L4.81(4.42,5.02)4.70(4.33,4.97)0.171LYM, ×109/L1.85 (1.63,2.13)1.80(1.35,2.24)0.182NEU, ×109/L3.20(2.69,3.78)4.45(3.38,6.17)<0.001PLT, ×109/L215(180.3,246.3)200(170.8,233.5)0.068NLR1.68(1.38,2.03)2.55(1.67,3.66)<0.001TC, mmol/L4.88(4.29,5.47)4.48(3.7,5.5)0.006TG, mmol/L1.27(1.01,1.65)1.31(1.03,1.94)0.299LDL-C, mmol/L2.90(2.28,3.55)2.63(2.13,3.39)0.062HDL-C, mmol/L1.26(1.11,1.45)1.14(0.97,1.31)<0.001FBG, mmol/L5.25(4.79,5.69)6.30(5.24,8.38)<0.001Abbreviations: BMI, Body Mass Index; WBC, white blood cell count; LYM, lymphocyte count; NEU, neutrophil count; NLR, neutrophil-to-lymphocyte ratio; RBC, red blood cell count; PLT, platelet count; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FBG, fasting blood glucose. Comparison of Demographic and Clinical Characteristics Between AIS and Controls Groups Abbreviations: BMI, Body Mass Index; WBC, white blood cell count; LYM, lymphocyte count; NEU, neutrophil count; NLR, neutrophil-to-lymphocyte ratio; RBC, red blood cell count; PLT, platelet count; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FBG, fasting blood glucose. Flow-chart describing the selection of AIS patients for the study. Serum HFREP1 Levels in the AIS and Control Groups Serum HFREP1 concentrations were significantly elevated in patients with AIS [47.30 (29.52, 83.37) ng/mL] relative to control subjects [25.02 (16.26, 35.26) ng/mL], with P<0.001, as shown in Figure 2A. Additional ROC curve analysis demonstrated that HFREP1 possessed a certain capacity to distinguish patients with AIS from healthy controls, with an AUC of 0.751 (95% CI:0.696–0.806, P<0.001). Additionally, the optimal HFREP1 cutoff value, defined as the threshold that maximizes the sum of sensitivity and specificity, was calculated as 35.35. At this cutoff, the corresponding sensitivity was 0.644 and specificity was 0.764 (Figure 2B). Figure 2Serum HFREP1 levels in AIS patients and controls. (A) Comparison of HFREP1 concentrations between AIS patients and controls. Serum HFREP1 levels were measured using an ELISA assay. (B) Performance of HFREP1 for discriminating AIS patients from controls. An ROC curve analysis was conducted to evaluate the diagnostic value of serum HFREP1 for AIS.The image A showing a dot plot of serum concentrations of HFREP1. The y axis label is, serum concentrations of HFREP1 left parenthesis ng slash ml right parenthesis, with a broken scale: 0 to 100 and 100 to 1000. Two groups on the x axis are labeled, CON and AIS. Individual points are plotted for each group, with horizontal and vertical summary bars. Text above reads, Z equals minus 6.917, P less than 0.001. The image B showing a receiver operating characteristic curve. The x axis label is, 100 percent minus Specificity percent, ranging 0 to 100. The y axis label is, Sensitivity percent, ranging 0 to 100. A diagonal reference line runs from left parenthesis 0, 0 right parenthesis to left parenthesis 100, 100 right parenthesis. The receiver operating characteristic curve rises from near left parenthesis 0, 0 right parenthesis toward left parenthesis 100, 100 right parenthesis. Text reads, AUC equals 0.751, P less than 0.001.Two plots showing serum HFREP1 concentrations by group and a receiver operating characteristic curve. Serum HFREP1 levels in AIS patients and controls. (A) Comparison of HFREP1 concentrations between AIS patients and controls. Serum HFREP1 levels were measured using an ELISA assay. (B) Performance of HFREP1 for discriminating AIS patients from controls. An ROC curve analysis was conducted to evaluate the diagnostic value of serum HFREP1 for AIS. Correlation of Serum HFREP1 Levels with NIHSS Scores, WBC, NEU, and NLR in AIS at Admission The results revealed a significant positive correlation between serum HFREP1 levels and NIHSS scores (rs=0.22, P=0.001), NEU count (rs=0.17, P<0.01), and NLR (rs=0.22, P<0.01) at admission. No significant correlation was observed between HFREP1 and WBC levels (rs= 0.11, P=0.09), as illustrated in Figure 3. Figure 3Correlation of HFREP1 with NIHSS scores and inflammation biomarkers. Spearman correlation analysis between serum HFREP1 levels and (A) NIHSS scores, (B) NLR, (C) NEU, and (D) WBC.Image A: Scatter plot with line, rs=0.22, P=0.001. HFREP1 (0-1000), NIHSS (0-30). Points cluster at HFREP1 0-150, NIHSS 0-10, some up to 25 at low HFREP1. One point at HFREP1 900, NIHSS 15. Line from NIHSS 4 at HFREP1 0 to NIHSS 12 at HFREP1 1000. Image B: Scatter plot with line, rs=0.22, P<0.01. HFREP1 (0-600), NLR (0-25). Points cluster at HFREP1 0-150, NLR 0-6, one high point at HFREP1 200, NLR 24. Line from NLR 3 at HFREP1 0 to NLR 6 at HFREP1 600. Image C: Scatter plot with line, rs=0.17, P<0.01. HFREP1 (0-1000), NEU (0-20). Points cluster at HFREP1 0-150, NEU 2-8, some up to 15 at low HFREP1. One point at HFREP1 900, NEU 12. Line from NEU 5 at HFREP1 0 to NEU 10 at HFREP1 1000. Image D: Scatter plot with line, rs=0.11, P=0.09. HFREP1 (0-1000), WBC (0-20). Points cluster at HFREP1 0-150, WBC 4-12, some up to 18 at low HFREP1. One point at HFREP1 950, WBC 14. Line from WBC 7 at HFREP1 0 to WBC 11 at HFREP1 1000.A set of four scatter plots showing correlations between HFREP1 and NIHSS, NLR, NEU and WBC. Correlation of HFREP1 with NIHSS scores and inflammation biomarkers. Spearman correlation analysis between serum HFREP1 levels and (A) NIHSS scores, (B) NLR, (C) NEU, and (D) WBC. Relationship Between HFREP1 and Admission Stroke Severity in AIS Of the total participants, 184 (82.9%) were diagnosed with mild stroke, and 38 (17.1%) suffered from moderate-to-severe stroke (Table 2). In the univariate analysis, serum HFREP1 concentrations were significantly higher in patients with moderate-to-severe stroke [75.16 (41.13, 108.1) ng/mL] than in those with mild stroke [43.10 (27.16, 75.58) ng/mL; P<0.001], as presented in Figure 4A.Table 2Baseline Characteristics of Mild Stroke and Moderate-to-Severe StrokeCharacteristicsTotal AIS(n=222)MildAIS (n=184)Moderate to Severe AIS (n=38)PAge, years66(59.75,72)66(60,71.75)66(56,73.25)0.661Male, n (%)152(68.47)129(70.1)23(60.5)0.247BMI, kg/m224.0(22.43,26.0)24.2(22.5,26.3)23.3(22.1,25)0.071Medical history, n (%)Hypertension, n (%)163(73.42)138(75)25(65.8)0.242Hyperlipidemia, n (%)26(11.71)22(12)4(10.5)0.803Diabetes mellitus, n (%)87(39.19)74(40.2)13(34.2)0.49Atrial fibrillation, n (%)23(9.91)16(8.7)7(18.4)0.073Ischemic heart disease, n (%)13(5.86)10(5.43)3(7.89)0.47Admission hyperglycemia, n (%)66(29.72)54(29.35)12(31.58)0.845Drinking history, n (%)54(24.3)50(27.2)4(10.5)0.029Smoking history, n (%)75(33.8)64(34.8)11(28.9)0.489TOAST subtypes, n (%)LAA209(94.1)171(92.9)38(100)0.091SAO4(1.8)4(2.2)0(0)0.359CE8(3.6)8(4.3)0(0)0.19SOE&SUE1(0.45)1(0.5)0(0)0.649SBP, mmHg148(132,162.5)149.68±1.69146.21±3.720.374DBP, mmHg89(81,96.5)89(81,97)84(76,95.3)0.187Time from stroke onset to blood collected, hours16(7,25)18(7,29)13(6,24.25)0.108Time from stroke onset to hospital arrival, hours9(5,24)10(6,24)6(3.5,12)0.008Posterior circulation, n (%)38(17.1)32(17.39)6(15.79)>0.999Acute treatmentEVT, n (%)12(5.4)2(1.1)10(26.3)<0.001IVT, n (%)17(7.7)16(8.7)1(2.6)0.201Medicine use during hospitalization, n (%)Antihypertensive drugs, n (%)128(57.7)106(57.6)22(57.9)0.974Hypoglycemic agents, n (%)87(39.2)76(41.3)11(28.9)0.155Antiplatelet agents, n (%)193(86.9)162(88)31(81.6)0.282Anticoagulant agents, n (%)21(9.5)19(10.3)2(5.3)0.332Lipid-lowering agents, n (%)202(91)170(92.4)32(84.2)0.109Admission NIHSS3(2,4.5)2(2,4)9(6,14.25)<0.001Admission mRS2(1,4)2(1,3)4(4,5)<0.001RBC, ×1012/L4.7(4.33,4.97)4.7(4.33,4.97)4.7(4.27,5.1)0.776WBC, ×109/L7.22(5.9,8.81)7.17(5.82,8.78)7.64(6.09,9.48)0.401LYM, ×109/L1.80(1.35,2.24)1.84 (1.38,2.31)1.67(1.16,1.93)0.04NEU, ×109/L4.45(3.38,6.17)4.43(3.34,5.97)4.97(3.83,7.55)0.141PLT, ×109/L200(170.75,233.5)200(173,233)200.5(162.5,241.8)0.629TC, mmol/L4.48(3.7,5.5)4.46(3.7,5.4)4.51(3.7,5.79)0.653TG, mmol/L1.31(1.03,1.94)1.36(1.03,1.98)1.22(0.98,1.74)0.183LDL-C, mmol/L2.63(2.13,3.39)2.63(2.14,3.24)2.63(2,3.89)0.39HDL-C, mmol/L1.14(0.97,1.31)1.11(0.97,1.32)1.16(1.02,1.31)0.489FBG, mmol/L6.30(5.24,8.38)6.29(5.09,8.28)6.39(5.69,9.06)0.157NLR2.48(1.62,3.56)2.43(1.6,3.35)2.94(1.69,5.41)0.168Abbreviations: BMI, Body Mass Index; TOAST, Trial of Org 10,172 in Acute Stroke Treatment; LAA, Large-artery atherosclerosis; SAO, Small artery occlusion; CE, Cardioembolism; SOE, Stroke of other determined etiology; SUE, Stroke of undetermined etiology; SBP, systolic blood pressure; DBP, diastolic blood pressure; EVT, endovascular therapy; IVT, intravenous thrombolysis; NIHSS, the National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; RBC, red blood cell count; WBC, white blood cell count; NEU, neutrophil count; LYM, lymphocyte count; PLT, platelet count; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; NLR, neutrophil-to-lymphocyte ratio. Figure 4Association between HFREP1 and initial stroke severity in AIS patients. (A) Serum HFREP1 levels in patients with mild and moderate-to-severe AIS. (B) ROC curve analysis showing the ability of HFREP1 to discriminate stroke severity in patients with AIS.Image A displays a scatter plot of HFREP1 serum concentrations by AIS severity. The plot indicates a significant difference (Z = -3.193, P < 0.001). The x-axis categorizes Mild AIS and Moderate to severe AIS, while the y-axis measures HFREP1 levels (ng/ml) from 0 to 1000. Mild AIS points cluster between 20-60, with outliers at 520 and 580. Moderate to severe AIS points range from 30-120, with an outlier at 900. Both groups have central markers with error bars. Image B shows a receiver operating characteristic curve. The x-axis is labeled 100% minus Specificity%, ranging from 0 to 100 and the y-axis is labeled Sensitivity%, also ranging from 0 to 100. A diagonal reference line runs from (0, 0) to (100, 100), with a stepped curve indicating performance (AUC = 0.665, P < 0.01).A scatter plot and a receiver operating characteristic curve showing HFREP1 and AIS stroke severity. Table 2Baseline Characteristics of Mild Stroke and Moderate-to-Severe StrokeCharacteristicsTotal AIS(n=222)MildAIS (n=184)Moderate to Severe AIS (n=38)PAge, years66(59.75,72)66(60,71.75)66(56,73.25)0.661Male, n (%)152(68.47)129(70.1)23(60.5)0.247BMI, kg/m224.0(22.43,26.0)24.2(22.5,26.3)23.3(22.1,25)0.071Medical history, n (%)Hypertension, n (%)163(73.42)138(75)25(65.8)0.242Hyperlipidemia, n (%)26(11.71)22(12)4(10.5)0.803Diabetes mellitus, n (%)87(39.19)74(40.2)13(34.2)0.49Atrial fibrillation, n (%)23(9.91)16(8.7)7(18.4)0.073Ischemic heart disease, n (%)13(5.86)10(5.43)3(7.89)0.47Admission hyperglycemia, n (%)66(29.72)54(29.35)12(31.58)0.845Drinking history, n (%)54(24.3)50(27.2)4(10.5)0.029Smoking history, n (%)75(33.8)64(34.8)11(28.9)0.489TOAST subtypes, n (%)LAA209(94.1)171(92.9)38(100)0.091SAO4(1.8)4(2.2)0(0)0.359CE8(3.6)8(4.3)0(0)0.19SOE&SUE1(0.45)1(0.5)0(0)0.649SBP, mmHg148(132,162.5)149.68±1.69146.21±3.720.374DBP, mmHg89(81,96.5)89(81,97)84(76,95.3)0.187Time from stroke onset to blood collected, hours16(7,25)18(7,29)13(6,24.25)0.108Time from stroke onset to hospital arrival, hours9(5,24)10(6,24)6(3.5,12)0.008Posterior circulation, n (%)38(17.1)32(17.39)6(15.79)>0.999Acute treatmentEVT, n (%)12(5.4)2(1.1)10(26.3)<0.001IVT, n (%)17(7.7)16(8.7)1(2.6)0.201Medicine use during hospitalization, n (%)Antihypertensive drugs, n (%)128(57.7)106(57.6)22(57.9)0.974Hypoglycemic agents, n (%)87(39.2)76(41.3)11(28.9)0.155Antiplatelet agents, n (%)193(86.9)162(88)31(81.6)0.282Anticoagulant agents, n (%)21(9.5)19(10.3)2(5.3)0.332Lipid-lowering agents, n (%)202(91)170(92.4)32(84.2)0.109Admission NIHSS3(2,4.5)2(2,4)9(6,14.25)<0.001Admission mRS2(1,4)2(1,3)4(4,5)<0.001RBC, ×1012/L4.7(4.33,4.97)4.7(4.33,4.97)4.7(4.27,5.1)0.776WBC, ×109/L7.22(5.9,8.81)7.17(5.82,8.78)7.64(6.09,9.48)0.401LYM, ×109/L1.80(1.35,2.24)1.84 (1.38,2.31)1.67(1.16,1.93)0.04NEU, ×109/L4.45(3.38,6.17)4.43(3.34,5.97)4.97(3.83,7.55)0.141PLT, ×109/L200(170.75,233.5)200(173,233)200.5(162.5,241.8)0.629TC, mmol/L4.48(3.7,5.5)4.46(3.7,5.4)4.51(3.7,5.79)0.653TG, mmol/L1.31(1.03,1.94)1.36(1.03,1.98)1.22(0.98,1.74)0.183LDL-C, mmol/L2.63(2.13,3.39)2.63(2.14,3.24)2.63(2,3.89)0.39HDL-C, mmol/L1.14(0.97,1.31)1.11(0.97,1.32)1.16(1.02,1.31)0.489FBG, mmol/L6.30(5.24,8.38)6.29(5.09,8.28)6.39(5.69,9.06)0.157NLR2.48(1.62,3.56)2.43(1.6,3.35)2.94(1.69,5.41)0.168Abbreviations: BMI, Body Mass Index; TOAST, Trial of Org 10,172 in Acute Stroke Treatment; LAA, Large-artery atherosclerosis; SAO, Small artery occlusion; CE, Cardioembolism; SOE, Stroke of other determined etiology; SUE, Stroke of undetermined etiology; SBP, systolic blood pressure; DBP, diastolic blood pressure; EVT, endovascular therapy; IVT, intravenous thrombolysis; NIHSS, the National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; RBC, red blood cell count; WBC, white blood cell count; NEU, neutrophil count; LYM, lymphocyte count; PLT, platelet count; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; NLR, neutrophil-to-lymphocyte ratio. Baseline Characteristics of Mild Stroke and Moderate-to-Severe Stroke Abbreviations: BMI, Body Mass Index; TOAST, Trial of Org 10,172 in Acute Stroke Treatment; LAA, Large-artery atherosclerosis; SAO, Small artery occlusion; CE, Cardioembolism; SOE, Stroke of other determined etiology; SUE, Stroke of undetermined etiology; SBP, systolic blood pressure; DBP, diastolic blood pressure; EVT, endovascular therapy; IVT, intravenous thrombolysis; NIHSS, the National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; RBC, red blood cell count; WBC, white blood cell count; NEU, neutrophil count; LYM, lymphocyte count; PLT, platelet count; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; NLR, neutrophil-to-lymphocyte ratio. Association between HFREP1 and initial stroke severity in AIS patients. (A) Serum HFREP1 levels in patients with mild and moderate-to-severe AIS. (B) ROC curve analysis showing the ability of HFREP1 to discriminate stroke severity in patients with AIS. Additionally, patients in the moderate-to-severe stroke group exhibited higher rates of EVT, as well as greater admission NIHSS and mRS scores, relative to those with mild stroke. By contrast, the moderate-to-severe subgroup showed a lower prevalence of drinking history, a shorter interval from stroke onset to hospital admission, and reduced lymphocyte counts (Table 2). Multivariate logistic regression further demonstrated that baseline HFREP1 levels were independently associated with severe stroke in Model 1 (OR=1.004, 95% CI: 1.000–1.007, P<0.05). This significant association remained stable after adjustment in Model 2 (OR=1.004, 95% CI: 1.000–1.008, P<0.05), Model 3 (OR=1.004, 95% CI: 1.000–1.007, P<0.05), and Model 4 (OR=1.004, 95% CI: 1.000–1.008, P<0.05) (Table 3). The AUC of HFREP1 for distinguishing stroke severity was 0.665 (95% CI: 0.573–0.756, P<0.01). The optimal cutoff value of 68.45 ng/mL yielded a specificity of 72.3% and a sensitivity of 60.5% for stratifying stroke severity (Figure 4B).Table 3Multivariate Logistic Regression Analysis of HFREP1 Associated with AIS SeverityModel 1Model 2Model 3Model 4POR95% CIPOR95% CIPOR95% CIPOR95% CIHFREP10.0311.0041.000–1.0070.0351.0041.000–1.0080.041.0041.000–1.0070.0391.0041.000–1.008Notes: Model 1: not adjusted; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex, smoking history, and drinking history; Model 4: adjusted for age, sex, smoking history, drinking history, posterior circulation, ischemic heart disease, and admission hyperglycemia.Abbreviations: CIs, confidence intervals; OR, odds ratio. Table 3Multivariate Logistic Regression Analysis of HFREP1 Associated with AIS SeverityModel 1Model 2Model 3Model 4POR95% CIPOR95% CIPOR95% CIPOR95% CIHFREP10.0311.0041.000–1.0070.0351.0041.000–1.0080.041.0041.000–1.0070.0391.0041.000–1.008Notes: Model 1: not adjusted; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex, smoking history, and drinking history; Model 4: adjusted for age, sex, smoking history, drinking history, posterior circulation, ischemic heart disease, and admission hyperglycemia.Abbreviations: CIs, confidence intervals; OR, odds ratio. Multivariate Logistic Regression Analysis of HFREP1 Associated with AIS Severity Notes: Model 1: not adjusted; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex, smoking history, and drinking history; Model 4: adjusted for age, sex, smoking history, drinking history, posterior circulation, ischemic heart disease, and admission hyperglycemia. Abbreviations: CIs, confidence intervals; OR, odds ratio. Predictive Values of HFREP1 for the Short-Term Prognosis of AIS According to the mRS at 90 days after discharge, 192 patients (86.49%) achieved a favorable prognosis, while 30 patients (13.51%) had an unfavorable outcome. Compared with the favorable outcome group, patients in the unfavorable outcome group presented significantly older age, a higher rate of endovascular treatment EVT, and elevated baseline NIHSS, admission mRS, HDL‑C and NLR levels (all P<0.05). In contrast, BMI and lymphocyte counts were markedly decreased in those with poor functional recovery (both P<0.05). There were no significant intergroup differences in conventional vascular risk factors, such as smoking history, alcohol intake, hypertension, diabetes, hyperlipidemia, and atrial fibrillation (all P>0.05) (Table 4).Table 4Baseline Characteristics of Stroke with Good and Poor OutcomeCharacteristicsTotal(n=222)Good Outcome(n=192)Poor Outcome(n=30)PAge, years66(59.75,72)65(59.25,70)71(62.5,74.25)0.027Male, n (%)152(68.47)133(69.27)19(63.33)0.515BMI, kg/m224.0(22.43,26.0)24.2(22.5,26.1)23.15(21.93,24.43)0.038Medical history, n (%)Hypertension, n (%)163(73.42)140(72.9)23(76.7)0.665Hyperlipidemia, n (%)26(11.71)22(11.5)4(13.33)0.766Diabetes mellitus, n (%)87(39.19)75(39.1)12(40)0.922Atrial fibrillation, n (%)23(9.91)19(9.9)4(13.33)0.566Ischemic heart disease, n (%)13(5.86)11(5.73)2(6.67)0.69Admission hyperglycemia, n (%)66(29.72)54(28.13)12(40)0.201Drinking history, n (%)54(24.3)47(24.5)7(23.3)0.892Smoking history, n (%)75(33.8)69(35.9)6(20)0.086TOAST subtypes, n (%)LAA209(94.1)181(94.3)28(93.3)0.839SAO4(1.8)2(1.04)2(6.67)0.089CE8(3.6)8(4.17)0(0)0.602SOE&SUE1(0.45)1(0.52)0(0)>0.05SBP, mmHg148(132,162.5)149±1.6150±50.153DBP, mmHg89(81,96.5)89(80,96)89.5(81,97.3)0.753Time from stroke onset to blood collected, hours16(7,25)16(7,25)15.25(5.6,28.8)0.661Time from stroke onset to hospital arrival, hours9(5,24)10(5,24)6.3(3.4,24)0.356Posterior circulation, n (%)38(17.1)32(16.67)6(20)0.609Acute treatmentEVT, n (%)12(5.4)5(2.6)7(23.3)<0.001IVT, n (%)17(7.7)15(7.8)2(6.7)0.826Medicine use during hospitalization (%)Antihypertensive, n (%)128(57.7)112(58.3)16(53.3)0.606Antidiabetic, n (%)87(39.2)76(39.6)11(36.7)0.761Antiplatelet, n (%)193(86.9)170(88.5)23(76.7)0.073Anticoagulant, n (%)21(9.5)19(9.9)2(6.7)0.574Lipid-lowering, n (%)202(91)176(91.7)26(86.7)0.374Admission NIHSS3(2,4.5)2(2,4)5(2.75,13.25)<0.001Admission mRS2(1,4)2(1,3)4(2,5)<0.001RBC, ×1012/L4.7(4.33,4.97)4.67±0.554.67±0.620.803WBC, ×109/L7.22(5.9,8.81)7.11(5.78,8.86)7.73(6.41,8.90)0.285LYM, ×109/L1.80(1.35,2.24)1.84 (1.36,2.31)1.67(1.15,1.94)0.044NEU, ×109/L4.45(3.38,6.17)4.42(3.30,6.16)5.46(3.78,6.66)0.115PLT, ×109/L200(170.75,233.5)200(170.3,234.5)202(169.5,240.3)0.834TC, mmol/L4.48(3.7,5.5)4.54(3.68,5.34)4.19(3.85,5.7)0.843TG, mmol/L1.31(1.03,1.94)1.32(1.04,1.96)1.07(0.84,1.93)0.149LDL-C, mmol/L2.63(2.13,3.39)2.67(2.12,3.29)2.54(2.19,3.58)0.958HDL-C, mmol/L1.14(0.97,1.31)1.11(0.97,1.3)1.25(1.06,1.44)0.03FBG, mmol/L6.30(5.24,8.38)6.27(5.12,8.18)6.59(5.50,9.37)0.14NLR2.48(1.62,3.56)2.48(1.62,3.56)3.27(2.09,5.52)0.025Abbreviations: BMI, Body Mass Index; TOAST, Trial of Org 10,172 in Acute Stroke Treatment; LAA, Large-artery atherosclerosis; SAO, Small artery occlusion; CE, Cardioembolism; SOE, Stroke of other determined etiology; SUE, Stroke of undetermined etiology; SBP, systolic blood pressure; DBP, diastolic blood pressure; EVT, endovascular therapy; IVT, intravenous thrombolysis; NIHSS, the National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; RBC, red blood cell count; WBC, white blood cell count; NEU, neutrophil count; LYM, lymphocyte count; PLT, platelet count; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; NLR, neutrophil-to-lymphocyte ratio. Table 4Baseline Characteristics of Stroke with Good and Poor OutcomeCharacteristicsTotal(n=222)Good Outcome(n=192)Poor Outcome(n=30)PAge, years66(59.75,72)65(59.25,70)71(62.5,74.25)0.027Male, n (%)152(68.47)133(69.27)19(63.33)0.515BMI, kg/m224.0(22.43,26.0)24.2(22.5,26.1)23.15(21.93,24.43)0.038Medical history, n (%)Hypertension, n (%)163(73.42)140(72.9)23(76.7)0.665Hyperlipidemia, n (%)26(11.71)22(11.5)4(13.33)0.766Diabetes mellitus, n (%)87(39.19)75(39.1)12(40)0.922Atrial fibrillation, n (%)23(9.91)19(9.9)4(13.33)0.566Ischemic heart disease, n (%)13(5.86)11(5.73)2(6.67)0.69Admission hyperglycemia, n (%)66(29.72)54(28.13)12(40)0.201Drinking history, n (%)54(24.3)47(24.5)7(23.3)0.892Smoking history, n (%)75(33.8)69(35.9)6(20)0.086TOAST subtypes, n (%)LAA209(94.1)181(94.3)28(93.3)0.839SAO4(1.8)2(1.04)2(6.67)0.089CE8(3.6)8(4.17)0(0)0.602SOE&SUE1(0.45)1(0.52)0(0)>0.05SBP, mmHg148(132,162.5)149±1.6150±50.153DBP, mmHg89(81,96.5)89(80,96)89.5(81,97.3)0.753Time from stroke onset to blood collected, hours16(7,25)16(7,25)15.25(5.6,28.8)0.661Time from stroke onset to hospital arrival, hours9(5,24)10(5,24)6.3(3.4,24)0.356Posterior circulation, n (%)38(17.1)32(16.67)6(20)0.609Acute treatmentEVT, n (%)12(5.4)5(2.6)7(23.3)<0.001IVT, n (%)17(7.7)15(7.8)2(6.7)0.826Medicine use during hospitalization (%)Antihypertensive, n (%)128(57.7)112(58.3)16(53.3)0.606Antidiabetic, n (%)87(39.2)76(39.6)11(36.7)0.761Antiplatelet, n (%)193(86.9)170(88.5)23(76.7)0.073Anticoagulant, n (%)21(9.5)19(9.9)2(6.7)0.574Lipid-lowering, n (%)202(91)176(91.7)26(86.7)0.374Admission NIHSS3(2,4.5)2(2,4)5(2.75,13.25)<0.001Admission mRS2(1,4)2(1,3)4(2,5)<0.001RBC, ×1012/L4.7(4.33,4.97)4.67±0.554.67±0.620.803WBC, ×109/L7.22(5.9,8.81)7.11(5.78,8.86)7.73(6.41,8.90)0.285LYM, ×109/L1.80(1.35,2.24)1.84 (1.36,2.31)1.67(1.15,1.94)0.044NEU, ×109/L4.45(3.38,6.17)4.42(3.30,6.16)5.46(3.78,6.66)0.115PLT, ×109/L200(170.75,233.5)200(170.3,234.5)202(169.5,240.3)0.834TC, mmol/L4.48(3.7,5.5)4.54(3.68,5.34)4.19(3.85,5.7)0.843TG, mmol/L1.31(1.03,1.94)1.32(1.04,1.96)1.07(0.84,1.93)0.149LDL-C, mmol/L2.63(2.13,3.39)2.67(2.12,3.29)2.54(2.19,3.58)0.958HDL-C, mmol/L1.14(0.97,1.31)1.11(0.97,1.3)1.25(1.06,1.44)0.03FBG, mmol/L6.30(5.24,8.38)6.27(5.12,8.18)6.59(5.50,9.37)0.14NLR2.48(1.62,3.56)2.48(1.62,3.56)3.27(2.09,5.52)0.025Abbreviations: BMI, Body Mass Index; TOAST, Trial of Org 10,172 in Acute Stroke Treatment; LAA, Large-artery atherosclerosis; SAO, Small artery occlusion; CE, Cardioembolism; SOE, Stroke of other determined etiology; SUE, Stroke of undetermined etiology; SBP, systolic blood pressure; DBP, diastolic blood pressure; EVT, endovascular therapy; IVT, intravenous thrombolysis; NIHSS, the National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; RBC, red blood cell count; WBC, white blood cell count; NEU, neutrophil count; LYM, lymphocyte count; PLT, platelet count; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; NLR, neutrophil-to-lymphocyte ratio. Baseline Characteristics of Stroke with Good and Poor Outcome Abbreviations: BMI, Body Mass Index; TOAST, Trial of Org 10,172 in Acute Stroke Treatment; LAA, Large-artery atherosclerosis; SAO, Small artery occlusion; CE, Cardioembolism; SOE, Stroke of other determined etiology; SUE, Stroke of undetermined etiology; SBP, systolic blood pressure; DBP, diastolic blood pressure; EVT, endovascular therapy; IVT, intravenous thrombolysis; NIHSS, the National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; RBC, red blood cell count; WBC, white blood cell count; NEU, neutrophil count; LYM, lymphocyte count; PLT, platelet count; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; NLR, neutrophil-to-lymphocyte ratio. Serum HFREP1 concentrations were markedly elevated in AIS patients with unfavorable functional outcomes compared with those with favorable outcomes [73.99 (33.66,118.03) ng/mL vs 44.95 (28.68,77.16) ng/mL, P<0.05] (Figure 5A). Figure 5Association between serum HFREP1 levels and functional outcomes in patients with AIS. (A) Serum HFREP1 levels in the AIS with good outcome versus poor outcome. (B) ROC curve analysis of HFREP1 for predicting 90-day functional prognosis in patients with AIS.Image A displays a scatter plot of HFREP1 serum concentrations. The x-axis distinguishes between good and poor prognosis, while the y-axis measures HFREP1 in nanograms per milliliter, with tick marks at 0, 40, 80, 120, 160, 200, then a break, followed by 200, 450, 700, 950. Annotation: Z = -2065, P < 0.05. For good prognosis, points cluster between 0-200 ng/mL, with outliers up to 600. Poor prognosis points are mostly 0-160, with outliers 200-300 and one near 900. Each group features a central bar with whiskers. Image B shows a receiver operating characteristic curve. The x-axis is 100% minus Specificity (%), ranging 0-100 and the y-axis is Sensitivity (%), also 0-100. A diagonal reference line runs from 0,0 to 100,100, with a stepped curve rising similarly. Text indicates AUC = 0.617, P < 0.05.A scatter plot and a receiver operating characteristic curve showing serum HFREP1 and prognosis groups. Association between serum HFREP1 levels and functional outcomes in patients with AIS. (A) Serum HFREP1 levels in the AIS with good outcome versus poor outcome. (B) ROC curve analysis of HFREP1 for predicting 90-day functional prognosis in patients with AIS. We further evaluated the prognostic value of serum HFREP1 for unfavorable outcomes following AIS. Univariate analysis revealed that elevated HFREP1 levels were associated with a higher risk of poor functional prognosis (P<0.05, Table 5). In multivariate logistic regression analysis (Model 2), HFREP1 still maintained a significant predictive effect on unfavorable outcomes in AIS patients (P<0.05, Table 5). However, after further adjusting for confounding variables, HFREP1 no longer showed a correlation with poor prognosis. ROC analysis results indicated that the optimal cut-off value of the serum HFREP1 level as an indicator for poor outcome was 68.45 ng/mL, yielding a sensitivity of 70.3% and a specificity of 56.7%, with an AUC of 0.617 (95% CI:0.503–0.732, P<0.05) (Figure 5B).Table 5Multivariate Logistic Regression Analysis of HFREP1 Associated with AIS OutcomeModel 1Model 2Model 3Model 4POR95% CIPOR95% CIPOR95% CIPOR95% CIHFREP10.0341.0041.000–1.0070.0411.0041.000–1.0070.0861.0031.000–1.0070.4281.0021.000–1.006Notes: Model 1: not adjusted; Model 2: adjusted for sex; Model 3: adjusted for age, sex, smoking history, drinking history; Model 4: adjusted for age, sex, smoking history, drinking history, baseline NIHSS, and EVT.Abbreviations: CIs, confidence intervals; OR, odds ratio. Table 5Multivariate Logistic Regression Analysis of HFREP1 Associated with AIS OutcomeModel 1Model 2Model 3Model 4POR95% CIPOR95% CIPOR95% CIPOR95% CIHFREP10.0341.0041.000–1.0070.0411.0041.000–1.0070.0861.0031.000–1.0070.4281.0021.000–1.006Notes: Model 1: not adjusted; Model 2: adjusted for sex; Model 3: adjusted for age, sex, smoking history, drinking history; Model 4: adjusted for age, sex, smoking history, drinking history, baseline NIHSS, and EVT.Abbreviations: CIs, confidence intervals; OR, odds ratio. Multivariate Logistic Regression Analysis of HFREP1 Associated with AIS Outcome Notes: Model 1: not adjusted; Model 2: adjusted for sex; Model 3: adjusted for age, sex, smoking history, drinking history; Model 4: adjusted for age, sex, smoking history, drinking history, baseline NIHSS, and EVT. Abbreviations: CIs, confidence intervals; OR, odds ratio. Discussion As far as we know, this is the first clinical investigation exploring serum HFREP1 expression and its clinical implications in patients with AIS. Our findings revealed markedly elevated serum HFREP1 levels in patients with AIS. Circulating HFREP1 concentrations were positively correlated with baseline NIHSS scores. Higher HFREP1 levels were linked to more severe neurological impairment and adverse short‑term prognosis, and this biomarker also showed moderate diagnostic performance in predicting poor clinical outcomes. Taken together, these observations indicate that serum HFREP1 serves as a promising novel biomarker for early severity stratification and prognostic evaluation in AIS patients. While the incidence and mortality rates of stroke in China have decreased over the past decade, the overall disease prevalence keeps increasing owing to population aging.20 For patients with IS, there remains a lack of accurate tools for early subtype diagnosis, disease progression prediction, and recurrence risk stratification before hospital admission. Insufficient understanding of the complex pathological mechanisms underlying IS has limited the development of personalized management and novel therapeutic strategies. In contrast to imaging biomarkers, which are widely used to guide acute treatments such as thrombolysis, molecular biomarkers in blood or other body fluids have not been incorporated into routine clinical practice. The major barrier is the lack of high-quality evidence, largely due to small sample sizes, inconsistent methodologies, and high population heterogeneity in previous studies.21 Mounting evidence indicates that inflammation is tightly linked to the onset and clinical prognosis of AIS. For instance, Hu et al reported that elevated leukocyte and neutrophil counts after intravenous thrombolysis are independently linked to poor 3-month outcomes in AIS patients.22 The pan-immune-inflammation value (PIV), an integrated index derived from neutrophils, platelets, monocytes and lymphocytes, has also emerged as a promising prognostic biomarker for patients receiving mechanical thrombectomy.23 Against this background, this study aimed to explore whether HFREP1, a newly identified inflammatory biomarker, could assess disease severity and predict short term clinical outcomes in patients with AIS. HFREP1 is a hepatic-derived acute inflammatory factor. Under stimulation by IL-6 and transforming growth factor-β (TGF-β), hepatocytes regulate the transcriptional expression of HFREP1 via the IL-6-JAK2-STAT3 and protein phosphatase 2A (PP2A)-hepatocyte nuclear factor-1 alpha (HNF-1α) signaling pathways. It regulates the proliferation, apoptosis, and chemoresistance of tumor via suppression of the protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and PP2A-HNF-1α signaling pathways.24 As a major ligand for LAG‑3, HFREP1 acts as an immune checkpoint that suppresses T-cell activity and is associated with PD‑1/PD‑L1 therapy resistance,25 making it a potential target for NSCLC14 and hepatocellular carcinoma immunotherapy.26 Additionally, HFREP1 is involved in obesity pathophysiology and represents a promising therapeutic candidate for obesity,27 as well as autoimmune and inflammatory diseases including RA28 and systemic lupus erythematosus (SLE).29 The observed elevation of serum HFREP1 in AIS could be primarily attributed to the stroke-induced systemic inflammatory response. Following AIS, local and systemic inflammatory cascades (eg, cytokine secretion, leukocyte activation, and blood-brain barrier breakdown) might result in the reprioritization of hepatic acute-phase proteins.30 Clarifying the molecular mechanisms that modulate HFREP1 expression is essential for developing novel therapeutic approaches against AIS, but the upstream mechanisms underlying its abnormal expression remain unclear. It is well known that IL-6 and STAT3 promote HFREP1 expression, although their specific molecular mechanisms remain unelucidated.31–33 We speculate that acute cerebrovascular injury triggers the prompt release of pro-inflammatory cytokines, including IL-6 and TNF-α, into the circulation, which act on hepatocytes to activate the transcription of acute-phase reactants, including HFREP1. As a histone lysine demethylase regulating gene transcription, KDM4A is upregulated under hypoxic conditions and has been linked to multiple pathological processes in IS: it promotes microglial polarization and exacerbates ischemic injury via the MDM2/CTRP3 axis,34 drives neutrophil infiltration by activating Cxcl1 in astrocytes in cooperation with NF-κB,35 and its inhibition improves post-ischemic functional recovery by suppressing NF-κB activation and neuroinflammation.36 Notably, KDM4A also regulates HFREP1 as its downstream molecule in non-small cell lung cancer (NSCLC),6 and whether KDM4A participates in neutrophil infiltration and the expression of inflammation-related factors (eg, IL-1β, TNF-α, VEGF) in AIS by regulating HFREP1 expression requires further investigation. Beyond its role as an inflammatory marker, elevated HFREP1 might reflect or contribute to the pathophysiological processes after AIS. However, further experimental investigations are needed to confirm these relationships. Specifically, HFREP1 has been confirmed to induce insulin resistance and lipid metabolism disorders via the ERK1/2 signaling pathway.7,37 In our study, serum HFREP1 was a significant predictor of poor 3-month outcomes, suggesting that it provides additional prognostic information beyond traditional clinical indicators. Thus, HFREP1 might serve as a critical mediator linking inflammation, metabolism, and stroke prognosis. Unlike traditional inflammatory markers, which merely indicate the level of inflammation and play no direct role in metabolic regulation, HFREP1 serves a dual function as both a biomarker and a potential pathological mediator-making it more clinically valuable. The prognostic value of serum HFREP1 further underscores its potential for clinical translation, a finding that is particularly meaningful for clinical practice. Serum HFREP1 can be detected rapidly and non-invasively using ELISA, without relying on specialized imaging equipment or subjective scoring systems. Preliminary evidence suggests that HFREP1 possesses potential prognostic value, and prospective validation is required before its clinical application for identifying high-risk individuals. Inflammatory responses are pivotal to the pathophysiological progression, therapeutic efficacy, and clinical prognosis of AIS. Peripheral blood leukocytes are recruited to the lesion site under the direction of inflammatory cytokines and chemokines secreted by ischemic tissues.38 Among the leukocyte system, neutrophils are the first circulating immune cells that increase in the short term after the onset of AIS. Neutrophils in the blood infiltrate into ischemic or infarcted tissues through the damaged blood-brain barrier and release inflammatory mediators, thereby increasing the risk of blood-brain barrier disruption, reperfusion injury, hemorrhagic transformation, and malignant cerebral edema.39 Conversely, lymphocyte counts were markedly reduced among patients with an unfavorable prognosis, which confirms the harmful effect of low lymphocyte count on long-term functional recovery after IS.40 As an objective and readily available marker of systemic inflammation, the NLR mirrors the balance between peripheral blood neutrophils and lymphocytes and has been extensively applied to evaluate systemic inflammatory status. Accumulating evidence demonstrates that increased NLR values are closely linked to atherosclerotic events and can act as a prognostic biomarker for coronary artery disease and IS.41,42 Especially in AIS patients with comorbid intracranial atherosclerotic stenosis, high NLR can independently predict the initial severity of stroke and short-term poor prognosis.43 Our study also found that the counts of leukocytes and neutrophils significantly increased in AIS patients, while the number of lymphocytes decreased. Furthermore, NLR levels were markedly higher in patients with an unfavorable prognosis. Multiple clinical and laboratory variables have been verified as independent predictors of functional outcomes after IS. Two recent multicenter longitudinal studies of Egyptian and Saudi Arabian patients receiving alteplase indicated that increased NIHSS, admission hyperglycemia, and post-thrombolytic intracerebral hemorrhage predict adverse 3-month outcomes of IS.44 Besides, for patients with embolic stroke, higher baseline NIHSS, heart failure, post-thrombolysis intracranial hemorrhage and recurrent symptomatic stroke independently forecast poor long-term functional prognosis.45 In addition, systemic inflammatory indicators including neutrophil count, NLR, and calprotectin reflect the magnitude of post-stroke neuroinflammation and are closely linked to prognosis.46,47 The present study observed that elevated serum HFREP1, an inflammation-related acute-phase protein, was correlated with stroke severity and 90-day functional outcomes. Nevertheless, the modest discriminatory ability of HFREP1 indicates that it cannot serve as a standalone powerful prognostic marker. Instead, HFREP1 may act as a supplementary inflammatory indicator combined with conventional risk factors to refine risk stratification for AIS patients. Several limitations of the present study should be acknowledged. First, this was a single-center retrospective observational study with a limited sample size, containing merely 38 patients with moderate-to-severe ischemic stroke and 30 individuals suffering from unfavorable 90-day functional outcomes. The limited number of outcome events may lead to wide confidence intervals and reduce the precision of effect estimates in multivariate regression models, which restricts the generalizability of our findings. Second, multiple statistical tests were conducted for baseline comparisons and correlation analyses without adjustments for multiple comparisons such as the Bonferroni method. As this work is exploratory in nature, formal correction was not applied. Accordingly, potential false-positive findings cannot be fully ruled out, and all statistical results need to be interpreted cautiously. Third, only admission serum HFREP1 concentrations were detected, and serial dynamic sampling was not performed. Therefore, temporal fluctuations in HFREP1 throughout stroke progression, treatment and recovery remain unknown, and the optimal time frame for HFREP1 testing needs further investigation. Fourth, subgroup analyses stratified by stroke subtypes were not carried out, and HFREP1 expression patterns may vary across different stroke subtypes. Notably, endovascular treatment (EVT) exhibited prominent imbalance between patients with favorable and unfavorable functional outcomes (2.6% versus 23.3%). EVT acts as a critical confounding variable influencing long-term neurological recovery. Fifth, statistically significant correlations were identified between HFREP1 and stroke severity as well as functional prognosis, yet the correlation coefficients were weak. The modest AUC values (0.665 for stroke severity and 0.617 for 90-day prognosis), together with a small incremental odds ratio (OR=1.004 per ng/mL, representing an approximately 4% increase in risk for every 10 ng/mL rise in HFREP1), suggest that HFREP1 possesses limited standalone discriminatory and predictive capacity for clinical practice. Finally, the mechanistic evidence is based on clinical correlation alone, further in vitro and in vivo experimental studies are required to clarify the precise molecular mechanisms through which HFREP1 affects stroke injury and recovery. Large-sample, multicenter prospective cohort studies are warranted to validate and refine the clinical predictive performance of HFREP1 in patients with AIS. Notwithstanding the above limitations, this study provides original preliminary evidence indicating that serum HFREP1 might serve as a biomarker with moderate discriminatory capacity for evaluating disease severity and predicting clinical prognosis in patients with AIS. Future research directions include validating the prognostic value of HFREP1 in large multicenter cohorts, exploring dynamic changes in serum HFREP1 levels and their correlation with stroke recovery, investigating the differential expression of HFREP1 across different stroke subtypes, and conducting basic experiments to clarify the functional role of HFREP1 in stroke pathophysiology. Further prospective validation would support the integration of HFREP1 measurement into conventional clinical workflows, helping refine risk stratification, inform therapeutic strategies, and optimize long-term functional recovery among AIS patients. Conclusion Serum HFREP1 levels are elevated in first‑onset AIS and correlate with disease severity. Baseline HFREP1 shows modest predictive ability for 3-month functional outcomes. These findings support further research into HFREP1 as a potential biomarker, but clinical use would require validation in larger, multicenter studies.